Form 4: Centessa CPO Sells Shares After Option Exercise

Centessa Pharmaceuticals' Chief People Officer, Karen M. Anderson, exercised stock options and subsequently sold a portion of her ordinary shares in March 2026.

Summary

• Karen M. Anderson, Chief People Officer of Centessa Pharmaceuticals plc, engaged in transactions involving the company's Ordinary Shares on March 16 and March 17, 2026.
• On March 16, 2026, Anderson acquired 64,768 Ordinary Shares through the exercise of stock options at a price of $4.01 per share.
• Immediately following the option exercise on March 16, 2026, she sold 64,768 Ordinary Shares at a weighted average price of $28.2079 per share, with individual sales ranging from $27.99 to $28.41.
• On March 17, 2026, Anderson acquired an additional 10,043 Ordinary Shares through the exercise of stock options at a price of $4.01 per share.
• Following this exercise on March 17, 2026, she sold 10,043 Ordinary Shares at a weighted average price of $28.1002 per share, with individual sales ranging from $27.99 to $28.21.
• All sales were conducted pursuant to a Rule 10b5-1 trading plan adopted by Anderson on November 12, 2025.
• After these transactions, Anderson's direct beneficial ownership of Ordinary Shares stands at 62,085.
• Remaining share options beneficially owned are 75,000, with a vesting schedule of 25% on December 1, 2023, and the remaining 75% in 36 monthly installments thereafter.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction, reflecting an executive's planned diversification and monetization of vested equity, rather than a signal of negative company performance. The pre-planned nature mitigates any negative sentiment associated with insider selling.

Positives

• The Chief People Officer realized a significant gain by exercising options at $4.01 and selling shares at weighted average prices of $28.2079 and $28.1002.
• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned and systematic management of equity compensation.

Negatives

• The transactions represent insider selling, which, while pre-planned, results in a reduction of the Chief People Officer's direct beneficial ownership in the company.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales executed under Rule 10b5-1 plans, are a common practice for executives to manage their personal finances, diversify their portfolios, and monetize vested equity. These pre-arranged plans are designed to provide an affirmative defense against claims of insider trading, as the trading decisions are made when the insider is not in possession of material non-public information.

Stakeholder Impact

• Shareholders might observe a reduction in direct insider ownership, but the pre-planned nature of the transactions under a Rule 10b5-1 plan suggests a routine financial management decision rather than a reaction to company-specific news.

Next Steps

• The remaining 75% of the share options will continue to vest in 36 monthly installments on the first day of each month following December 1, 2023.

Key Dates

Recommendation

The transactions represent a routine, pre-planned monetization of vested equity by an executive, not an indication of a change in company fundamentals or future prospects. Investors should not interpret this as a bearish signal but rather as a personal financial management decision, thus a 'hold' recommendation is appropriate as it does not alter the investment thesis for the stock.

Keywords

Centessa Pharmaceuticals, CNTA, Insider Trading, Form 4, Stock Options, Share Sale, Executive Compensation, Rule 10b5-1